BullFrog AI (BFRG) highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP with pancreatic cancer ...

FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer ...

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) ...

August 11, 2025 - Previous articles in this series have explored identification, preservation, collection, review and production of novel data sources, but I would be remiss if I left out the last, ...

Crinetics Pharmaceuticals, Inc. announced that eight abstracts detailing their clinical development programs will be presented at the Endocrine Society's Annual Meeting, ENDO 2025. The presentations ...

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory ...

- 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition - - Axatilimab abstracts highlight ...